CoChat

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Abstract

Objective This multicenter, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus conventional insulin aspart (IAsp) in adults with type 1 diabetes. Research design and methods The primary end point was change from baseline in HbA 1c after 26 weeks. After an 8-week run-in, subjects were randomized (1:1:1) to double-blind mealtime faster aspart ( n = 381), IAsp ( n = 380), or open-label postmeal faster aspart ( n = 382)-each with insulin detemir. Results HbA 1c was reduced in both treatment groups, and noninferiority to IAsp was confirmed for both mealtime and postmeal faster aspart (estimated treatment difference [ETD] faster aspart-IAsp, mealtime, -0.15% [95% CI -0.23; -0.07], and postmeal, 0.04% [-0.04; 0.12]); mealtime faster aspart statistically significantly reduced HbA 1c versus IAsp ( P = 0.0003). Postprandial plasma glucose (PPG) increments were statistically significantly lower with mealtime faster aspart at 1 h (ETD -1.18 mmol/L [95% CI -1.65; -0.71], -21.21 mg/dL [-29.65; -12.77]; P P = 0.0375) after the meal test; superiority to IAsp for the 2-h PPG increment was confirmed. The overall rate of severe or blood glucose-confirmed (plasma glucose Conclusions Faster aspart effectively improved HbA 1c , and noninferiority to IAsp was confirmed, with superior PPG control for mealtime faster aspart versus IAsp. Subjects randomized to postmeal faster aspart for all meals maintained HbA 1c noninferior to that o…

Overview

Integrity signals

Registry

Crossref · 10.2337/dc16-1771

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Research works printed but not linked: 5

  1. Andersen, 2015, Ultra-rapid BioChaperone insulin Lispro (BC-LIS): linear dose-response and faster absorption than insulin Lispro (LIS), Diabetologia, 58, S449
  2. Hirsch, 2014, Recombinant human hyaluronidase pretreatment of CSII cannula sites provides comparable glycemic control with reduced hypoglycemia in T1DM compared to usual CSII, Diabetes, 63, 85-LB
  3. Høiberg-Nielsen, 2016, Mechanistic analysis into the mode of action of niacinamide in faster-acting insulin aspart, Diabetes Technol Ther, 18, A291
  4. Rodbard, 2016, Adding faster-acting insulin aspart to basal insulin significantly improved glycemic control: the onset 3 trial, Diabetes, 65, A64
  5. 2016, Compatibility and safety of faster-acting insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes, Endocr Rev, 37, FRI697

Cited by

Items 101–177 of 177

Metadata

Authors
Russell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., Graungaard, T., & Bergenstal, R. M.
Affiliations
  • Royal Surrey County Hospital (GB)
  • Atlanta Diabetes Associates (US)
  • Department of Endocrinology, Diabetology, and Metabolism, Antwerp University Hospital, Antwerp, Belgium
  • Mossakowski Medical Research Institute, Polish Academy of Sciences (PL)
  • University of Sheffield (GB)
  • Universitair Ziekenhuis Leuven (BE)
  • Scripps Whittier Diabetes Institute, Scripps Health, San Diego, CA
  • Institute of Diabetes Research, Münster, Germany
  • University of Manitoba (CA)
  • Novo Nordisk (Denmark) (DK)
  • Park Nicollet Health Services (US)
Corresponding author
Russell-Jones, David
Venue
Diabetes Care
Published
2017-03-29
Volume
40
Issue
7
Pages
943-950
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2598553007
Cited by
177
References
23
Citations by year
2026: 5 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 21 · 2021: 22 · 2020: 23 · 2019: 22 · 2018: 35 · 2017: 14
FWCI
20.30
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
fast-acting insulin aspart, insulin aspart, type 1 diabetes, multiple daily insulin injections, insulin detemir, glycemic control, HbA1c, postprandial blood glucose, hypoglycemia, non-inferiority, mealtime insulin, insulin analogues, treat-to-target, adults with type 1 diabetes
MeSH terms
Insulin Detemir, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Male, Middle Aged, Body Mass Index, Postprandial Period, Endpoint Determination, Insulin Aspart, Meals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.